Treatments for Crohn’s disease (CD) or ulcerative colitis (UC) include anti-TNFs and novel therapies, but optimal real-world treatment sequencing has not been well-studied. This study compared healthcare resource use (HRU) and costs associated with switching from initial anti-TNF therapy to either vedolizumab (VDZ) or another anti-TNF.